Semaglutide, a weekly injectable GLP-1 agonist widely used for the treatment of type 2 diabetes mellitus (DM), has been approved since 2021 by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for chronic weight management in patients with obesity or body mass index (BMI) above 27 kg/m2andat least one weight-related condition. Here, GLP1R is linked to Obesity.